A pan-serotype antiviral to prevent and treat dengue: A journey from discovery to clinical development driven by public-private partnerships
Article
[키워드] ACTIV, an accelerating COVID-19 therapeutic interventions and vaccines
ADME, absorption distribution metabolism and excretion
BARDA, Biomedical Advanced Research and Development Authority
CD3, Center for Drug Design and Discovery
COVID-19, Coronavirus disease 2019
Dengue antiviral research and development
DENV, dengue virus
DVI, dengue vaccine initiative
EIF, European Investment Fund
FDA, Food and Drug Administration
GLP, good laboratory practice
GPH, global public health
IMI, Innovative Medicines Initiative
MMV, Medicines for Malaria Venture
MPD, Mectizan® Donation Program
NHP, non-human primates
NME, new molecular entity
NS, non-structural protein
NTD, neglected tropical disease
PPP, public-private partnership
public-private partnership
SAR, structure-activity-relationship
SARS-CoV-2, severe acute respiratory syndrome-coronavirus-2
TB, Tuberculosis
UNITE4TB, academia and industry united innovation and treatment for tuberculosis
WHO, World Health Organization
[DOI] 10.1016/j.antiviral.2022.105495 PMC 바로가기 [Article Type] Article
[DOI] 10.1016/j.antiviral.2022.105495 PMC 바로가기 [Article Type] Article